- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04173117
Feasibility of Low Energy Diet in HFpEF and Type 2 Diabetes (ALLEVIATE)
A Low-energy Meal Replacement Plan for Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aims of the proposed feasibility study are to assess whether a low-energy meal replacement plan (MRP) in patients with HFpEF and T2D:
1. Is acceptable to an older, co-morbid, multi-ethnic population
The secondary objectives are to assess whether a low-energy MRP in patients with HFpEF and T2D may be:
- associated with improved symptoms
- likely to lead to favourable cardiovascular reverse remodelling
- likely to improve functional capacity and quality of life
- associated with favourable reductions in cardiovascular biomarkers
- associated with increased physical activity
- associated with favourable cardiovascular outcomes
All patients will undergo the following assessments at baseline, 12-weeks and 12 months (following MRP):
- Anthropometry: height, weight, BMI.
- Haemodynamics: resting heart rate and blood pressure.
- 6-minute walk test +/- cardiopulmonary exercise test (if able to perform)
- CMR: contrast enhanced, stress perfusion CMR
- MLWHFQ
- WHODAS 2.0 (12-item version)
- Fasting blood test: full blood count, urea and electrolytes, HbA1c, fasting glucose, BNP, high-sensitivity troponin I, insulin and C-peptide. Plasma (≈35mL) will be stored for future biomarker analysis including metabolomics.
- Urinalysis for proteinuria and urine protein/creatinine ratio.
- Body composition; dual-energy X-ray absorptiometry (DEXA) scanning.
12. At the end of the 12-week intervention, participants will be invited to a semi-structured interview to explore qualitative aspects of the study to guide future trial design.
13. At 12 months attendance at cardiac rehabilitation will be reviewed.
The MRP provided by Cambridge Weight Plan® contains ~810 kcal/day (30% protein, 50% carbohydrate, 20% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Grace Walters
- Phone Number: 01162044723
- Email: gwmw1@leicester.ac.uk
Study Contact Backup
- Name: Emer M Brady
- Phone Number: 01162044723
- Email: emb29@le.acuk
Study Locations
-
-
Leicestershire
-
Leicester, Leicestershire, United Kingdom, LE3 9QP
- Cardiovascular Research Centre (Glenfield Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Established T2D (HbA1c ≥6.5%, duration >3months)
- Obesity (BMI ≥30 or ≥27 kg/m2 if black/south Asian ethnicity)
- Symptoms limiting exercise capacity in normal daily activities (dyspnoea or fatigue) or an established diagnosis of HF
- Diagnosis of HFpEF in accordance with European Society of Cardiology criteria: LV EF >50% with objective evidence of cardiac structural or functional alterations (LV hypertrophy (≥12mm); LV mass index ≥115g/m2 for males and ≥95g/m2 for females; E/e' ≥13 and a mean e' septal and lateral wall <9 cm/s; left atrial volume index >34mL/m2 or reduced global longitudinal strain (>-18%); elevated levels of natriuretic peptides (B-type natriuretic peptide >35pg/mL and/or NT-pro B-type natriuretic peptide >125pg/mL))
Exclusion Criteria:
- Unwilling to undertake MRP (low energy diet)
- HBa1c >10%
- Diabetes duration >12 years
- High-dose insulin requirement: either on full basal-bolus insulin regime or insulin requirement >1U/kg/day
- Have been on insulin treatment >10 years
- Current treatment with anti-obesity drugs
- Diagnosed eating disorder or purging
- Weight loss > 5kg in preceding 3 months (unless related to hospitalisation for HF)
- Absolute contraindications to MRI
- Severe renal impairment eGFR<30ml/min/m2
- Myocardial infarction within preceding 6 months
- History of substance abuse
- Cancer undergoing active treatment
- Unable to consent due to lack of mental capacity
- Pregnancy/considering pregnancy
- People unable to perform activities of daily living independently or unable attend for clinical appointments without a carer/attendant
- Unable to read/understand English sufficiently to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Low energy meal replacement plan 12 weeks
|
Low energy meal replacement plan (12 weeks)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment and retention rates
Time Frame: 16 weeks
|
The number of people approached, recruited and retained
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in 6 minute walk test pre- and post intervention
Time Frame: 12 weeks
|
Meters walked within 6 minutes
|
12 weeks
|
Differences in cardiopulmonary exercise test (peak VO2) pre- and post intervention
Time Frame: 12 weeks
|
exercise test on a static bike using minute by minute ventilatory gas analysis
|
12 weeks
|
Differences in LV remodelling (indexed LV mass) pre- and post intervention
Time Frame: 12 weeks
|
CMR measures of cardiac geometry
|
12 weeks
|
Differences in LV function pre- and post intervention
Time Frame: 12 weeks
|
CMR measures of cardiac function
|
12 weeks
|
Differences in E/A ratio pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in E (cm/s) pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in MV deceleration time (ms) pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in A (cm/s) pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in Septal e' pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in Lateral e' pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in Septal E/e' pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in Lateral E/e' pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in Average E/e' pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in LA volume indexed pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in TR jet velocity (m/s) pre- and post intervention
Time Frame: 12 weeks
|
Standard clinical echocardiography
|
12 weeks
|
Differences in BMI pre- and post intervention
Time Frame: 12 weeks
|
Weighing scales and stadiometer measurement (Kg/m2)
|
12 weeks
|
Differences in Bone Mineral Density (g/cm2) pre- and post intervention
Time Frame: 12 weeks
|
DEXA scan
|
12 weeks
|
Differences in Total Fat mass (g) pre- and post intervention
Time Frame: 12 weeks
|
DEXA scan
|
12 weeks
|
Differences in Total tissue fat (%) pre- and post intervention
Time Frame: 12 weeks
|
DEXA scan
|
12 weeks
|
Differences in visceral adipose tissue mass (g) pre- and post intervention
Time Frame: 12 weeks
|
DEXA scan
|
12 weeks
|
Differences in visceral adipose tissue volume (cm3) pre- and post intervention
Time Frame: 12 weeks
|
DEXA scan
|
12 weeks
|
Differences in Total lean body mass (g) pre- and post intervention
Time Frame: 12 weeks
|
DEXA scan
|
12 weeks
|
Difference in World Health Organisation Disability Schedule (WHODAS 2.0) pre- and post intervention
Time Frame: 12 weeks
|
Scale 0 - 48 with lower scores indicating better outcome
|
12 weeks
|
Difference in Medical Research Council Dyspnoea Scale pre- and post intervention
Time Frame: 12 weeks
|
scale 1 - 5 with lower scores indicating better outcome
|
12 weeks
|
Difference in Minnesota Living with heart Failure Questionnaire pre- and post intervention
Time Frame: 12 weeks
|
Scale 0 - 105 with lower scores indicating better outcome
|
12 weeks
|
Differences in Fasting Glucose (mmol/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in HbA1c (%) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in HbA1c (mmol/mol) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in B-type (ng/L) natriuretic peptide pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in hs-troponin (ng/L) natriuretic peptide pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in CRP (mg/L), natriuretic peptide pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in albumin concentration pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in albumin/creatinine ratio concentration pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in sodium (mmol/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in potassium (mmol/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in Urea (mmol/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in creatinine (umol/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in eGFR (ml/min) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in hsTnl(ng/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in hALT (iu/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in ALP (iu/L)pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in LDL (mmol/L) pre- and post intervention
Time Frame: 12 weeks
|
Biochemistry
|
12 weeks
|
Differences in kidney function pre- and post intervention
Time Frame: 12 weeks
|
Blood analysis for eGFR (ml/min)
|
12 weeks
|
Differences in liver function pre- and post intervention
Time Frame: 12 weeks
|
Blood analysis for ALP (iu/L)
|
12 weeks
|
Differences in the levels of physical activity pre- and post intervention
Time Frame: 12 weeks
|
Objectively measured with an accelerometer
|
12 weeks
|
Cardiac rehabilitation uptake
Time Frame: 12 months
|
The proportion of participants who were offered and attended cardiac rehabilitation following completion of the intervention (%)
|
12 months
|
The number of participants who experience any Major Adverse Cardiovascular Events (MACE)
Time Frame: 12 weeks
|
At any point during the study if a participant experiences a major cardiovascular event this will be recorded and reported to sponsor in line with handling serious adverse events
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 0699
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dietary Exposure
-
Loughborough UniversityKyowa Hakko Bio Co., Ltd.CompletedDietary ExposureUnited Kingdom
-
Oregon Health and Science UniversityCompleted
-
Société des Produits Nestlé (SPN)Enrolling by invitationDietary ExposureUnited Kingdom
-
University of North Carolina, Chapel HillThe Bloomberg Family Foundation, Inc.CompletedDietary ExposureUnited States
-
Universitas Katolik Widya Mandala SurabayaCompletedDietary ExposureIndonesia
-
Société des Produits Nestlé (SPN)Recruiting
-
Washington University School of MedicineMichigan State University; Project Peanut Butter, Ghana; College of Health Sciences...Completed
-
International Agency for Research on CancerFederico II University; Imperial College London; Fondazione IRCCS Istituto Nazionale... and other collaboratorsCompleted
-
Martin-Luther-Universität Halle-WittenbergNot yet recruitingSafety Issues | Dietary Exposure
-
Northumbria UniversityCompletedMetabolic Disturbance | Dietary ExposureUnited Kingdom
Clinical Trials on Low energy meal replacement plan (12 weeks)
-
University of GlasgowUniversity of Ghana; University of StirlingCompletedUndernutrition | UnderweightUnited Kingdom
-
Imperial College LondonCompletedOverweight | Metabolic Syndrome | Obese | Non Alcoholic Fatty Liver DiseaseUnited Kingdom
-
Oviva UK LtdUniversity of WestminsterActive, not recruiting
-
Aarhus University HospitalUnknown
-
Texas Tech UniversityNestléCompleted
-
University of NottinghamUniversity of BirminghamUnknownOverweight and ObesityUnited Kingdom
-
Region Örebro CountyUnknownObesity | Weight Loss | Non-Alcoholic Fatty Liver DiseaseSweden
-
Assistance Publique - Hôpitaux de ParisCompletedLung Cancer | Non Small Cell Lung CancerFrance
-
University of LeicesterUniversity of Oxford; University of ManchesterRecruitingDiabetes Mellitus, Type 2 | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction | Diabetes Mellitus Type 2 in Obese | Obesity Adult OnsetUnited Kingdom
-
National Taiwan University HospitalUnknown